首页 > 市场调查报告书 > 製药

生技设备基因治疗学和RNAi

市场调查报告书

商品编码

1572521

细胞活力检测市场、机会、成长动力、产业趋势分析与预测，2024-2032

Cell Viability Assays Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月21日 | 出版商:

Global Market Insights Inc. | 英文 265 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023 年，全球细胞活力检测市场价值为 17 亿美元，预计在预测期内复合年增长率为 8.5%。这种增长是由精准医学的日益普及和生物技术的进步所推动的，从而刺激了对可靠和准确的细胞活力测试的需求。此外，癌症和心血管疾病等慢性疾病的盛行率不断上升，凸显了对高效药物发现过程和新疗法的需求，而这在很大程度上依赖于细胞活力测定。

该市场受益于临床试验和早期药物测试的激增，以及细胞和分子生物学研究活动的扩大。研究和开发资金的增加，加上自动化分析和高通量筛选等先进技术的采用，进一步推动了市场的扩张。

细胞活力测定在毒理学、药物开发和细胞生物学等各种生物医学研究领域中至关重要，因为它们评估细胞在特定环境下的生存和功能能力。这些测定对于确定化学物质、治疗或环境变化对细胞健康的影响至关重要。

市场根据产品、应用、最终用户和地区进行细分。

2023 年，由于日常研究必不可少的试剂、检测试剂盒和微孔板的频繁使用，消耗品领域占据了 62.4% 的市场份额。在应用方面，由于对干细胞治疗的需求不断增长，干细胞研究的价值为7.133亿美元。对再生医学的日益关注以及干细胞在疾病建模和个人化医疗中的广泛应用也有助于该细分市场的成长。

在最终用户中，生物製药和製药公司预计将以 8.6% 的复合年增长率成长，因为它们在药物开发中严重依赖细胞活力测定。监管要求和研发方面的大量投资进一步支撑了该领域的主导地位。

2023 年，北美细胞活力检测市场规模达 6.96 亿美元，预计复合年增长率为 8.3%。光是美国在先进技术、支持性监管架构和大量研究投资的推动下，2023 年的销售额就达到 6.41 亿美元，预计到 2032 年将达到 13 亿美元。美国市场受益于其采用尖端技术，提高了细胞活力测试的准确性和效率。

产业生态系统分析
产业影响力
- 成长动力
  - 增加药物发现和开发
  - 基于细胞的检测的进展
  - 加强干细胞研究
- 产业陷阱与挑战
  - 先进检测和仪器的高成本
  - 技术复杂，需要专业知识
成长潜力分析
监管环境
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

主要趋势
耗材
- 检测试剂盒
  - 四唑还原测定试剂盒
    - MTT检测
    - MTS 检测
    - XTT 检测
    - 其他四唑还原测定试剂盒
  - 刃天青细胞活力测定试剂盒
  - Calcein-AM 细胞活力测定试剂盒
  - 其他检测试剂盒
- 试剂
- 微孔板
仪器仪表
- 分光光度计
- 流式细胞仪
- 自动细胞计数器
- 显微镜检查
- 细胞成像和分析系统

第 6 章：市场估计与预测：按应用分类，2021 - 2032

主要趋势
干细胞研究
药物发现与开发
基础研究
临床和诊断应用
其他应用

第 7 章：市场估计与预测：按最终用户划分，2021 - 2032 年

主要趋势
生物製药和製药公司
CRO 和 CMO
学术及研究机构
诊断实验室

第 8 章：市场估计与预测：按地区划分，2021 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

Abcam plc
Abnova Corporation
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
BioTek Instruments, Inc. (Agilent Technologies, Inc.)
Biotium, Inc.
Canvax Biotech S.L.
Creative Bioarray, Inc.
Danaher Corporation
Geno Technology, Inc.
GE Healthcare Technologies, Inc.
Merck KGaA
PerkinElmer, Inc.
Promega Corporation
Thermo Fisher Scientific Inc.

简介目录

Product Code: 10906

The Global Cell Viability Assays Market was valued at USD 1.7 billion in 2023 and is projected to grow at a CAGR of 8.5% over the forecast period. This growth is driven by the increased adoption of precision medicine and advancements in biotechnology, fueling the demand for reliable and accurate cell viability testing. In addition, the rising prevalence of chronic diseases, such as cancer and cardiovascular disorders, underscores the need for efficient drug discovery processes and novel therapeutics, which heavily rely on cell viability assays.

The market benefits from a surge in clinical trials and early-stage drug testing, alongside expanding research activities in cellular and molecular biology. Increased funding for research and development, coupled with the adoption of advanced technologies like automated assays and high-throughput screening, further propels the market expansion.

Cell viability assays are essential in various biomedical research fields, including toxicology, drug development, and cell biology, as they assess a cell's ability to survive and function under specific circumstances. These assays are critical for determining the effects of chemicals, treatments, or environmental changes on cell health.

The market is segmented based on Product, Application, End-user, and Region.

In 2023, the consumables segment dominated with a 62.4% market share, driven by the frequent use of reagents, assay kits, and microplates, which are essential for routine research. In terms of applications, stem cell research was valued at USD 713.3 million, driven by the rising demand for stem cell-based treatments. The growing focus on regenerative medicine and the broad applications of stem cells in disease modeling and personalized medicine also contribute to the segment growth.

Among end-users, biopharmaceutical and pharmaceutical companies are expected to grow at 8.6% CAGR, as they heavily rely on cell viability assays in drug development. Regulatory requirements and substantial investments in research and development further support this segment's dominance.

North America accounted for USD 696 million in the cell viability assays market in 2023, with a projected growth rate of 8.3% CAGR. The U.S. alone accounted for USD 641 million in 2023 and is expected to reach USD 1.3 billion by 2032, driven by advanced technology, a supportive regulatory framework, and significant investments in research. The U.S. market benefits from its adoption of cutting-edge technologies, enhancing the accuracy and efficiency of cell viability testing.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increased drug discovery and development
  - 3.2.1.2 Advancements in cell-based assays
  - 3.2.1.3 Increasing stem cell research
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of advanced assays and instruments
  - 3.2.2.2 Technical complexity requiring expertise
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Consumables
- 5.2.1 Assay kits
  - 5.2.1.1 Tetrazolium reduction assay kits
    - 5.2.1.1.1 MTT assays
    - 5.2.1.1.2 MTS assays
    - 5.2.1.1.3 XTT assays
    - 5.2.1.1.4 Other tetrazolium reduction assay kits
  - 5.2.1.2 Resazurin cell viability assay kits
  - 5.2.1.3 Calcein-AM cell viability assay kits
  - 5.2.1.4 Other assay kits
- 5.2.2 Reagents
- 5.2.3 Microplates
5.3 Instruments
- 5.3.1 Spectrophotometers
- 5.3.2 Flow cytometers
- 5.3.3 Automated cell counters
- 5.3.4 Microscopy
- 5.3.5 Cell imaging and analysis systems

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Stem cell research
6.3 Drug discovery and development
6.4 Basic research
6.5 Clinical and diagnostic applications
6.6 Other applications

Chapter 7 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Biopharmaceutical and pharmaceutical companies
7.3 CROs and CMOs
7.4 Academic and research institutes
7.5 Diagnostic laboratories

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa